TRACON Pharmaceuticals IncOTCQB:TCON
- LAST PRICE0.0295
- TODAY'S CHANGE (%)-0.0005 (-1.6667%)
- Bid / Lots0.0001/ 100
- Ask / Lots0.3500/ 25
- Open / Previous Close0.0500 / 0.0300
- Day Range
- 52 Week Range
- Volume3,679
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCON |
|---|---|---|
| 10:29 ET | 2000 | 0.05 |
| 10:38 ET | 917 | 0.0295 |
| 10:44 ET | 150 | 0.0295 |
| 12:57 ET | 200 | 0.0418 |
| 02:03 ET | 180 | 0.0295 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TRACON Pharmaceuticals Inc | 100.5K | 0.0x | --- |
Todos Medical Ltd | 2.1K | 0.0x | --- |
Immunoprecise Antibodies Ltd | 10.0M | -0.5x | --- |
Medicure Inc | 6.6M | -3.2x | --- |
LakeShore Biopharma Co Ltd | 49.0M | -0.5x | --- |
Rosetta Genomics Ltd | 590.0 | 0.0x | --- |
Company Information
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
Contact Information
- Headquarters
- 4350 LA JOLLA VILLAGE DRIVE, SUITE 800SAN DIEGO, CA, United States 92122
- Phone
- 858-550-0780
- Fax
- 302-636-5454
Executives
- President, Chief Executive Officer, Treasurer, Company Secretary, Director
- Craig Jalbert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $100.5K |
|---|---|
Revenue (TTM) | $3.2M |
Shares Outstanding | 3.4M |
TRACON Pharmaceuticals Inc does not pay a dividend. | |
Beta | 1.36 |
EPS | $3.79 |
Book Value | $-0.37 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | 0.0x |
Operating Margin | -228.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
